CN Patent

CN104230886A — 阿昔替尼新晶型

Assigned to Nanjing Huawe Medicine Technology Development Co Ltd · Expires 2014-12-24 · 11y expired

What this patent protects

本发明涉及一种阿昔替尼，化学名为N-甲基-2-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲哚-6-基]硫基]苯甲酰胺的新晶型。本发明亦涉及一种用于制备该阿昔替尼晶型A的方法。

USPTO Abstract

本发明涉及一种阿昔替尼，化学名为N-甲基-2-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲哚-6-基]硫基]苯甲酰胺的新晶型。本发明亦涉及一种用于制备该阿昔替尼晶型A的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN104230886A
Jurisdiction
CN
Classification
—
Expires
2014-12-24
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Huawe Medicine Technology Development Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.